Last reviewed · How we verify
NVG-291
At a glance
| Generic name | NVG-291 |
|---|---|
| Sponsor | NervGen Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NVG-291 in Spinal Cord Injury Subjects (PHASE1, PHASE2)
- A Phase I Safety Study of NVG-291 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVG-291 CI brief — competitive landscape report
- NVG-291 updates RSS · CI watch RSS
- NervGen Pharma portfolio CI